Literature DB >> 9405445

Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria.

G Liu1, K Nellaiappan, H M Kagan.   

Abstract

Homocysteine thiolactone, selenohomocysteine lactone, and homoserine lactone were found to be competitive, irreversible inhibitors of lysyl oxidase, with KI values of 21 +/- 3 microM, 8.3 +/- 2.2 microM, and 420 +/- 56 microM, respectively. The first order rate constants for inactivation (k2) of the enzyme varied over a much smaller range, ranging from 0.12 to 0.18 to 0.28 min-1 for the Se-, thio-, and O-lactones, respectively. Mutually exclusive labeling of the enzyme by [1-14C]beta-aminopropionitrile, [U-14C]phenylhydrazine, or [35S]homocysteine thiolactone was observed. These labeling results, together with the closely similar perturbations of the near UV-visible spectra of lysyl oxidase and of a model of its lysine tyrosylquinone cofactor by the thiolactone, indicate that the lactones likely derivatize and reduce the active site carbonyl cofactor. Substitution with deuterium at the alpha-carbon of the thiolactone caused a deuterium kinetic isotope effect on k2 of 3.2 +/- 0.2, consistent with the involvement of rate-limiting alpha-proton abstraction during lactone-induced inactivation of the enzyme. The activities of plasma amine oxidase and diamine oxidase were only minimally reduced at concentrations of the sulfur or selenium lactones that fully inhibited lysyl oxidase. Thus, these lactones constitute a new category of mechanism-based inactivators selective for lysyl oxidase. Further, these results may relate to the development of connective tissue defects seen in homocystinuria.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9405445     DOI: 10.1074/jbc.272.51.32370

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Relation of plasma total homocysteine, folate and vitamin B12 levels to bone mineral density in Moroccan healthy postmenopausal women.

Authors:  Zhor Ouzzif; Khalid Oumghar; Karim Sbai; Aziza Mounach; El Mustapha Derouiche; Abdellah El Maghraoui
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

Review 2.  Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition).

Authors:  Yoshiki Nishizawa; Hiroaki Ohta; Masakazu Miura; Masaaki Inaba; Schoichi Ichimura; Masataka Shiraki; Junichi Takada; Osamu Chaki; Hiroshi Hagino; Saeko Fujiwara; Masao Fukunaga; Takami Miki; Noriko Yoshimura
Journal:  J Bone Miner Metab       Date:  2012-11-10       Impact factor: 2.626

3.  Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase.

Authors:  Takumi Maruhashi; Isao Kii; Mitsuru Saito; Akira Kudo
Journal:  J Biol Chem       Date:  2010-02-24       Impact factor: 5.157

4.  Homocysteine suppresses the expression of the collagen cross-linker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation.

Authors:  Roman Thaler; Marlies Agsten; Silvia Spitzer; Eleftherios P Paschalis; Heidrun Karlic; Klaus Klaushofer; Franz Varga
Journal:  J Biol Chem       Date:  2010-12-09       Impact factor: 5.157

Review 5.  The Effects of Homocysteine on the Skeleton.

Authors:  Mitsuru Saito; Keishi Marumo
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 6.  The role of homocysteine in bone remodeling.

Authors:  Thomas P Vacek; Anuradha Kalani; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Clin Chem Lab Med       Date:  2013-03-01       Impact factor: 3.694

Review 7.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.

Authors:  M Saito; K Marumo
Journal:  Osteoporos Int       Date:  2010-02       Impact factor: 4.507

Review 8.  The contribution of collagen crosslinks to bone strength.

Authors:  Patrick Garnero
Journal:  Bonekey Rep       Date:  2012-09-19

9.  Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours.

Authors:  Carlotta Granchi; Tiziana Funaioli; Janine T Erler; Amato J Giaccia; Marco Macchia; Filippo Minutolo
Journal:  ChemMedChem       Date:  2009-10       Impact factor: 3.466

Review 10.  Hypoxia and the extracellular matrix: drivers of tumour metastasis.

Authors:  Daniele M Gilkes; Gregg L Semenza; Denis Wirtz
Journal:  Nat Rev Cancer       Date:  2014-05-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.